Breast Cancer

The FDA held a Type B meeting regarding the use of d3-T, a form of testosterone, and the risk of developing breast cancer in women.

Paxalisib combined with pembrolizumab and chemotherapy showed preliminary activity in patients with metastatic triple-negative breast cancer.

The BC-RADS-2 study aimed to address diagnostic delays and cancer care disparities of patients with breast cancer in low- and middle-income countries.

In the ASCENT-04/KEYNOTE-D19 trial, sacituzumab govitecan plus pembrolizumab significantly extended PFS in patients with first-line metastatic TNBC.

The FDA accepted the NDA for gedatolisib for HR+/HER2–, PIK3CA wild-type advanced breast cancer after it reduced the risk of disease progression or death.

The marketing authorization was based on results from the DESTINY-Breast09 trial assessing T-DXd/pertuzumab in first-line HER2+ metastatic breast cancer.

Investigators used the NCCN Distress Thermometer to identify psychological distress in Nigerian patients with breast cancer in a cross-sectional study.

Researchers highlight the importance of geriatric assessments and patient-centered outcomes to manage unique physiological and functional challenges in older breast cancer survivors.

Previously, the phase 2 EVANGELINE trial assessed treatment with (Z)-endoxifen in this patient group.

Nurses preferred the FreedomEDGE infusion system compared with the manual push technique in a retrospective survey study.

VCU Massey Cancer Center is utilizing L-Dex bioimpedance spectroscopy to move toward a preventative model for lymphedema.

Data from a phase 2 study may support a novel mTOR inhibitor-based regimen in previously treated, HR-positive, HER2-negative breast cancer.

The addition of zovegalisib to fulvestrant led to rapid declines in PIK3CA and ESR1 ctDNA in the HR-positive/HER2-negative advanced breast cancer group.

Safety data from ASCENT-03 support sacituzumab govitecan as an effective therapy with manageable toxicities in advanced triple-negative breast cancer.

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Results from the DESTINY-Breast05 trial revealed that T-DXd was superior to T-DM1 in these patients with HER2-positive early breast cancer.

Unadjusted post-recurrence OS was numerically lower with palbociclib plus endocrine therapy vs endocrine therapy alone in the phase 3 PALLAS trial.

“VIKTORIA-1 is the first study to demonstrate a statistically significant and clinically meaningful improvement in PFS with PAM inhibition in patients with PIK3CA wild-type disease, all of whom received prior CDK4/6 inhibition,” said Barbara Pistilli, MD.

Data from the phase 3 PHILA study support pyrotinib plus trastuzumab as a therapeutic strategy in HER2-positive metastatic breast cancer.

Data from the PREFER study may provide evidence for improving oncofertility counseling for premenopausal women with early breast cancer.

“This trial supports the value of a functional RAD51-based HRD assessment to refine patient selection for PARP inhibitors,” said Isabel Pimentel, MD.

The risk of pain deterioration was similar with T-DXd/pertuzumab vs standard of care in the DESTINY-Breast09 trial.

Subgroup data from the phase 3 DESTINY-Breast05 trial further characterize the clinical benefit of T-DXd over T-DM1 in this breast cancer population.

Sessions from SABCS 2025 detailed potential advances across different immunotherapy, radiation, and surgical modalities in breast cancer care.

Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.